Cancer Genome Sequencing Market will Grow at a Strong Rate Through 2023

Over the last few years, the genomic era of cancer studies is developing at a rapid pace fueled by the emergence of next-generation sequencing technology rendering exquisite resolution and sensitivity. Frequent alterations in their gross chromosomal structure by means of amplification, deletion and inversion of their chromosomal structure forms a characteristic feature of cancer genome. These gene alterations or modifications ultimately lead to cancer onset and progression. 

Additionally, the gene sequencing for cancer has several advantages over traditional approaches which include the ability to perform complete gene sequencing in single test including the detecting copy number alterations, translocations, and exome-wide base substitutions in all related cancer cells. The reduction in the cost associated with whole genome sequencing and overall time required to perform these sequencing has drastically reduced in last couple of years. A study published by TheHuffingtonPost.com, Inc. in 2013 illustrated that five years ago expenses for performing whole genome sequencing were in millions of dollars which currently can be performed solely for few thousand dollars. Numerous technological advancements have significantly contributed in advancing the research studies pertaining to cancer diagnosis and treatment. Despite this the recombinant DNA cloning is still in its infancy and is yet not competent enough in unraveling the full complexity of the human cell.  

Previously, a new genome sequencing test developed at Memorial Sloan Kettering known as MSK-IMPACT made cancer analysis far more comprehensive and can be used on any type of solid tumor, irrespective of its location in the human body. According to the scientists of Memorial Sloan Kettering, cancer identification and its predisposition can benefit patients, health practitioners and eventually help in reducing the morbidity and mortality with respect to cancer. A study by Johns Hopkins scientists published in April 2015 illustrated that in last few years several hospitals and companies have collaborated to sequence patient’s tumor in an attempt to personalize therapy for cancer treatment. In addition to selecting personalized therapies for patients with cancer, sequencing the normal tissue genome can also increase the overall understanding of cancer, including finding reasons for cancer predisposition due to germline genome changes. 

Regulations pertaining to personalized cancer sequencing are primarily governed by the accreditation of the laboratories performing the sequencing services and analysis, and also the usage of FDA approved tests for conducting these tests. Drivers to the cancer genome sequencing encompass comprehensive view of whole genome, ability to majority of mutations, and eliminating the need for having any prior knowledge about the patient history and current disease status. Such potential growth attributors are likely to boost the demand for gene sequencing-based personalized cancer treatment in the near future. High procedural cost and time consuming interpretation of large data sets are among the key restraints to the market. An alternative to the whole genome sequencing is the targeted gene sequencing method that is comparative less costly, with easy results interpretation and high sensitivity for rare clones. 

Avail a Sample Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4619

Geographically, the market is studied for four regions; North America, Europe, Asia Pacific and Rest of the World. North America market includes the United States and Canada which form the major revenue contributors owing to increasing inclination towards gene therapy-based cancer treatment. The region is followed by Europe which has also initiated several genome-based studies in cancer. An analysis conducted by Genomics England Ltd. in 2014, revealed that the U.K. is set to become the world leader in ground breaking genetic research into cancer and rare diseases post a grant of USD 473.3 million by Prime Minister of U.K. Asia Pacific and Rest of the World are still in nascent stage owing to the need for high initial investment on laboratory set-up and conducting research activity. However the APAC market is expected to grow in the forthcoming years due to availability of skilled and scientific-based manpower, strength in information technology and its growing economy. 

Some of the major companies operating in cancer genome sequencing market include Illumina, Inc., Beckman Coulter Genomics, SeqWright, BGI Americas Corporation, Pacific Biosciences, Ambry Genetics, and Foundation Medicine. 

Non-invasive Prenatal Testing - A 360-degree View of the Market!

The close association between maternal age and the risk of developing chromosomal abnormalities in fetuses is common knowledge. Rising maternal age leads to an increased prevalence rate of babies born with a variety of diseases associated with chromosomal abnormalities. The Down Syndrome Education (DSE) association states that rate of occurrence of Down syndrome is about one in every 830 cases of child birth in the U.S. and about one in every 920 cases in Europe every year.

A variety of conventional prenatal genetic tests such as chorionic villus sampling (CVS) and amniocentesis involve invasive methods and carry the risk of facing a miscarriage. The rising population of women preferring pregnancy at later ages and technological advancements in the field of non-invasive prenatal tests allowing more accurate and extremely risk-free tests are driving an increased demand for non-invasive prenatal test (NIPT) technologies. Most new NIPTs analyze the cell-free DNA in the maternal plasma hence, they involve absolutely no risk of miscarriage resulting from the test.

Global NIPT Market at a Glance

According to the research report’s estimates, the global non-invasive prenatal testing market was worth US$0.5 bn in 2013 and is expected to grow at an incredible CAGR of 17.50% from 2014 to 2022 to reach a figure of US$2.4 bn by 2022. The impressive growth of the global non-invasive prenatal testing market is mainly due to the growing chances of fetuses developing chromosomal disorders such as Down syndrome, Turner syndrome, Edwards syndrome, Patau syndrome, and others. Non-invasive prenatal testing equipment is used for screening pregnant women who might have fetuses with these complications due to, among other reasons, higher maternal age than average.

Avail a Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

The global non-invasive prenatal testing market is segmented on the basis of test and region. The tests in this market are Harmony, MaterniT21 PLUS, NIFTY, BambniTest, informaSeq, Panorama, VisibiliT, PrenaTest, verify, and others. Geographically, the global non-invasive prenatal testing market is segmented into Europe, Asia Pacific, North America, and Rest of the World.

All of these tests use the mother’s blood to study the cell-free fetal DNA. Back in 2011, MaterniT21 PLUS was the first ever non-invasive prenatal test launched in the market for diagnosing trisomy 21. Over the course of two years, this diagnostic test had already grabbed a share of 36.1% in the overall market. However, analysts predict that as the popularity of other testing equipment such as NIFTY, Panorama, and verify grows, MaterniT21 PLUS’ share will drop. Furthermore, demand for the Bambni test, which was recently approved by the CFDA, will also shoot upwards in the coming years.

Unfortunately, the global non-invasive prenatal testing market faces certain hurdles such as a tough regulatory framework and conservative ethical outlook towards prenatal testing. The other challenges complicating this situation are limitations of non-invasive prenatal tests and alternative screening and testing methods. However, the emerging economies of Asia Pacific are offering a new avenue for growth to the global non-invasive prenatal testing market in the near future.

Some of the important companies profiled in the global non-invasive prenatal testing market report are Laboratory Corporation of America Holdings, Natera Inc., Illumina Inc., Berry Genomics Co. Ltd., LifeCodexx AG, BGI Diagnostics, Sequenom Inc., and Ariosa Diagnostics Inc. The research report gives a complete understanding of the competitive landscape of the market and offers an insight into the financial overview, product portfolio, research and development activities, business and marketing strategies, and investment outlook in the coming years.

Genome Engineering Market to Grab the Largest Market Share by 2023

Genome engineering refers to the strategies and techniques implemented for the modification of target genetic information of any living organism. During the last few years, research spending has increased in gene editing technologies covering number of patents and research papers published exponentially. Synthetic biology received funding of US$ 430 Mn in the U.S. from 2005 to 2010, which was much higher than US$ 160 Mn in Europe during the same period. About 4% and 2% funding was spent on exploring ethical, social, and legal implications (ELSI) of synthetic biology in the U.S. and Europe, respectively.

Genome Engineering Market -  Global Industry Analysis, Size, Share, Growth, Trends, and Forecast

2015 - 2023”, the Genome Engineering Market was valued at US$2.20 bn in 2014 and is projected to expand at a CAGR of 14.2% from 2015 to 2023.

Genome engineering technologies include Clustered regularly-interspaced short palindromic repeats (CRISPR), Transcription activator-like effector nuclease (TALEN), Zinc finger nuclease (ZFN) and other technologies, while the other technologies include antisense technology and recombinant AAV mediated genome engineering. Of these, CRISPR held the majority share of the market in 2014, followed by TALEN. CRISPR has been identified as the fastest growing segment during the forecast period, as it is cost-effective with high precision. CRISPR method is used for wide variety of disorders like sickle-cell anemia, HIV/AIDS, hemophilia and several forms of cancers. These techniques are in different stages of clinical development with a focus on modifying the genetic material of somatic cells.

Avail a Sample Research Report on Genome Engineering Market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4671

Based on application, the cell line engineering segment accounted major share of the global genome engineering market in terms of revenue. Moreover, the segment is expected to gain market share and emerge as the fastest growing segment during the forecast period. Pharmaceutical and Biotechnology companies segment would grow as a fastest growing end-user segment with major share in the market.

North America is the largest regional markets for genome engineering in 2014, accounting for more than half of the market share. The region dominated due to high government funding in research and the presence of direct presence of key players in the region. Asia Pacific was identified as the fastest growing market for genome engineering in 2014 due to high spending in academic research which would also propel its market in near future.

The key players in genome engineering market are Thermo Fisher Scientific, Inc., Sigma-Aldrich Corporation, Sangamo Biosciences, Inc., Lonza Group Ltd., Horizon Discovery Group Plc, Integrated DNA Technologies, Inc., are among the others.  Thermo Fisher Scientific, Inc was identified as the leading player in the global Genome engineering market in 2014. 

Healthcare Cold Chain Logistics Market to be Driven by Advent of Biologics, Bulging Pharmaceutical Trade

Transportation and logistics is becoming a progressively more important part of the healthcare industry as it bends backward to ensure that drugs reach consumer at the right place at the right time and most importantly, with uncompromised safety. The development of biologics will further boost spends on healthcare cold chain logistics, says Transparency Market Research in its report, titled, ‘Healthcare Cold Chain Logistics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.’

According to the report, there is a conspicuous rise in the demand for cold chain logistics in the healthcare industry thanks to substances such as blood plasma, tissues, pharmaceutical products, and sensitive chemicals being transported both domestically and internationally. A variety of other drugs – such as birth control pills, dermatological therapies, and anti-depressants – are sensitive to heat, moisture and moisture. This, too, necessitates the reliance on healthcare cold chain logistics.

Some of the most common mediums of transportation used in the healthcare cold chain logistics market are: reefer ships, containers, reefer cars, and refrigerated trucks. The need for dependable healthcare cold chain logistics is even greater in underserved regions with harsh or variable climatic conditions where patients usually suffer because of the lack of a proper logistical network. Thus, companies in the healthcare cold chain logistics market will find growth opportunities in developing and underdeveloped regions.

For a highly detailed study, the report segments the global healthcare cold chain logistics market on the basis of products, logistics techniques, and geography. By product type, the market is segmented into vaccines, biopharmaceuticals, and clinical trial materials. On the basis of techniques, the market is composed of liquid nitrogen, dry ice, and gel packs. These segments are studied for the period ranging from 2013 to 2019.

Read more: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1888

The mammoth size of the healthcare industry, which has been lately been shaped by the advent of biological drugs, in itself presents a massive playing field for companies in the healthcare cold chain logistics market. The WHO pegs the worth of the global pharmaceutical industry at US$300 bn as of 2015. Bulging pharmaceutical trade volumes will help this industry stand at approximately US$ 400 bn before 2020. Companies such as India are now exporting more drugs every year to feed the rising demand for medicines – a trend that augurs well for the global healthcare cold chain logistics industry.

Companies that are studied in the Company Profiles section of the report include:

DHL International GmbH, Kuehne and Nagel International AG, FedEx Corporation, Continental Air Cargo, LifeConEx, LLC, DB Schenker, Inc., United Parcel Service Inc.,  and World Courier.

The global healthcare cold chain logistics market is categorized based on the following:

·         By products

o    Biopharmaceuticals

o    Vaccines

o    Clinical trial materials

·         By techniques

o    Dry ice

o    Liquid nitrogen

o    Gel packs

Healthcare Industry to Grow due to Cutting-Edge Technologies Being Introduced By IT and Telecom Sectors

IT supports the healthcare industry by handling a number of peripheral and core operations of the industry. The functions of IT range from patient data storage to patient health monitoring to the presentation of optimal therapies for patients. Various cutting-edge technologies such as SaaS, telecom-centric solutions, and cloud computing have been specifically developed for the healthcare industry. The advent of telecom has also resulted in healthcare providers leveraging their conventional medical care resources such as clinics, hospitals, and equipment across a broader remote patient base. In addition, telecom providers have fulfilled the rising demand from the healthcare industry for greater bandwidth, mobility solutions, and high-performance technologies. 

 

Strategic decision making needs to be based on verifiable data, as one false step in an intensely competitive environment could mean millions of dollars lost. The report thus takes a close look at the healthcare market specifically from the standpoint of the IT and telecom industry. Opportunities for the monetization of healthcare processes form a key component of the report. Major geographies, latest market trends, and projected growth figures are cohesively documented in the report. This data forms the foundation for recommendations for future growth.

Request a Brochure for more Details: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=99

Advancements in telecommunications and IT have made it possible to monitor patients remotely and also to use more accurate methodologies to diagnose and treat medical conditions. As a result, the quality of medical care available to patients in the developing world is poised to greatly improve. Round-the-clock monitoring has been made possible with the use of intelligent IT and telecom solutions in the health industry. Telemedicine is an area that holds immense potential, and medical establishments are looking at opportunities for investment here. Thus, the demand for IT and telecommunications products in the healthcare sector will continue to see an upward trend in the coming years.

Moving further, the report states that the development in telecommunications has also enabled remote patient monitoring as well as accurate methodologies for the treatment and diagnosis of medical conditions. This is why the quality of medical care is predicted to immensely improve in emerging economies in the coming years. Further, the report states that 24/7 monitoring is made possible by the implementation of telecom and IT in the healthcare industry. This has resulted in an increasing demand for telecommunications and IT products within the healthcare industry and this demand is poised to increase in forthcoming years, as per this study.

The report states that owing to rising usage of interconnected networks as well as electronic health records (EHR), collaboration will be seen amongst care teams, clinicians, and organizations for optimization of treatment resources in the healthcare industry. In the last section of the report, the healthcare industry has been segmented on the basis of geography into North America, Europe, Asia Pacific, and Rest of the World (RoW). Data regarding the performance of each regional segment is given in the report.

Read more: http://www.transparencymarketresearch.com/healthcare-it-telecom.html

Cell Culture Media, Sera, and Reagents Market to reach US$7.1 bn by 2023

The global cell culture media, sera, and reagents market has registered impressive growth in recent past. The rising demand for biopharmaceuticals and artificial organs has propelled the global market to a significant extent. In 2014, the global cell culture media, sera, and reagents market stood at US$3.7 bn. Analysts expect the market to expand at a CAGR of 6.70% over the period of 2015-2023 and reach US$7.1 bn by the end of 2023. 

Cell Culture Media: Dominating Global Cell Culture Media, Sera, and Reagents Market

Media, sera, and reagents are the three major components of the global cell culture market. Among these, the market for cell culture media dominates the global cell culture media, sera, and reagents market. At present, the demand for cell culture media has been shifting from serum-based media to serum-sparing media, serum-free animal derived media, and chemically-defined media. The advancement in cell culture and cell productivity has led to the adoption of smaller procedures, employing single use equipment, which in turn, has raised the demand for ready-to-use media powders, and liquid media.

Macromolecules, carrier proteins, fetal bovine, low molecular weight nutrients, newborn calf and adult bovine sera, and hormones are the key products of the sera market. The sera market is expected to witness a sluggish growth on account of the risk of viral contamination associated with the insertion of serum from animal source.

Cell dissociation reagents, cell freezing media, extracellular attachment matrices, cell washing solutions, and amino acids are the most common reagents available across the globe. These reagents are utilized to detect or synthesize another substance, which is under study in the culture. 

Request a Sample Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6598

North America: Leading Regional Market for Cell Culture Media, Sera, and Reagents

On the regional front, the global market for cell culture media, sera and reagents has been distributed among North America (Canada and the U.S.), Europe (the U.K., Germany, and the Rest of Europe), Asia Pacific (China, Japan, Korea, India, and the Rest of Asia Pacific), Latin America (Mexico, Brazil, and the Rest of Latin America), and the Rest of the World (Russia and Israel).

In 2014, the cell culture media, sera and reagents market in North America acquired the leading position, accounting for more than 40% of the overall market. The favorable government policies to encourage life sciences projects and stem cell research contribute to the significant growth of this industry in North America.

On the other hand, the Asia Pacific cell culture media, sera, and regents market is likely to post the fastest growth in the global market over the period from 2015 to 2023. Of late, a rise in the number of market participants in emerging economies of Asia Pacific is evident in the regional market. This trend, coupled with the emerging trend of outsourcing research processes, is expected to boost the market for cell culture media, sera, and regents in this region.

Global Cell Culture Media, Sera, and Reagents Market: Competitive Landscape

The global cell culture media, sera, and reagents market is highly concentrated in nature with a few established players. However, the untapped opportunities presented by emerging economies across the world have encouraged a large number of small cap companies to venture into this market.

Becton, Dickinson and Co., EMD Millipore, Corning Life Sciences B.V., GE Healthcare, PromoCell GmbH, Lonza Group Ltd., Sigma-Aldrich Co. LLC, VWR International LLC, Thermo Fisher Scientific Inc., and Wheaton Industries Inc. are some of the major participants in the global market for cell culture media, sera, and reagents.

Epidermal Growth Factor Receptor Antibodies Market to Boom in 2016

The epidermal growth factor receptor (EGFR) is defined as a transmembrane tyrosine kinase receptor involved in the survival and proliferation of the cancerous cells. Any kind of mutations affecting these EFGR receptors or activity could results in cancer. Mutations lead to over-expresion resulting in large number of cancer, including lung cancer, anal cancer and glioblastoma multiforme. EGFR receptors are the first molecule target against which monoclonal antibodies (mAb) have been designed for cancer treatment. 

These monoclonal antibodies are sometimes also referred as EGFR antibodies. EGFR antibodies market can be segmented on the basis of the major antibodies which are used against EGFR receptors which include:

• Cetuximab
• Panitumumab
• Nimotuzumab

Cetuximab (erbitux) and panitumumab (vecitibix) are the most preferred biosimilar EGFR antibodies which are used for treatment of cancer. These antibodies have demonstrated efficacy in the treatment of colorectal cancer as single agents and in combination with conventional chemotherapy. Since the US Food and Drug Administration (FDA) had approved cetuximab in 2003 and panitumumab in 2006, EGFR antibodies have become primary step of treatment algorithms for colorectal cancer. However, nimotuzumab is a humanized monoclonal antibody that as of 2014 is recognized under orphan drugs status in the U.S. and the European Union for the treatment of glioma. This drug has also achieved marketing approval in India and China for squamaus cell carcinoma of the neck and head, and is currently undergoing numerous clinical trials.

Additionally, many market players and research institutions are performing research activities on development of the biosuperior EGFR antibodies against cancerous cells. The most common biosuperior EGFR antibodies include engineered EGFR antibodies, Bi- and Multi-specific EGFR antibodies and EGFR antibody drug conjugates. As for instance, Hoffmann-La Roche is performing a phase 1b study of MPDL3280A (and engineered antibody) in combination with Tarceva in patients suffering from non-small cell lung cancer. Such extensive research and development activities associated with the development of EGFR antibodies biosuperiors is the major factor which is driving this market. However, the high cost associated with research activities and sunk cost involved in R&D activities restrains the EGFR antibodies market.

Moreover, the increasing incidence of cancer worldwide is also demanding for the more effective treatment methods, which is encouraging the researchers to develop EGFR antibodies. According to World Health Organization (WHO), cancer was the leading cause of death in 2012, accounting for 8.2 million deaths worldwide. Lung, liver, colorectal, stomach and breast cancers were responsible for most of the deaths every year. Statistics also revealed that breast cancer incidence had risen by more than 20% in 2012 from 2009, while breast cancer mortality rate has increased by 14%. Due to harsh lifestyle, excessive intake of alcohol and smoking habits, the incidence of cancer is increasing rapidly worldwide, especially in developed economies of North America and Europe. Increasing morbidity and mortality rate among the cancer patients is fuelling the demand for EGFR antibodies, hence driving the market.

Some of the market players which are actively contributing towards EGFR antibodies market include Amgen, Inc., Eisai, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer, Inc., Biocon Ltd., Takeda Pharmaceutical Company, Ltd. and Immunogen, Inc.

Read more: http://www.transparencymarketresearch.com/epidermal-growth-factor-receptor-antibodies-market.html

Biomaterials Market Research That Multiply your Investment!

In a latest research report published by Transparency Market Research (TMR) “Biomaterials Market for Implantable Devices - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”, the global biomaterials market is forecasted to grow at a CAGR of 4.1% between 2013 and 2019. According to the report, the market is estimated to be valued at US$33,600 million by 2019, increasing from US$25,277.8 million in 2012. Biomaterials are fabricated from either synthetic or natural origin materials that are used for medical implants. Heart valves, dental implants, artificial hip joints, and intraocular lenses are some of the commonly used medical implants for which biocompabitility and safety needs to be guaranteed, since these implants come in close proximity to internal organs in the human body. Owing to such reasons it necessary that biomaterials are biocompatible, which means they should not interfere with the physiology and not cause any immunogenic reaction in the human body.

Growth Drivers and Opportunities 

According to the findings of this market research report, the biomaterials market for implantable

devices will find a remunerative consumer base in the aging population that is pushing up the demand for graft transplants and medical implants. The average life expectancy of humans is on the rise, and continues to increase in densely populated emerging countries. 

A growing incidence of diseases such as osteoporosis and arthritis will continue to propel the need for medical implants, which in turn utilize biomaterials. The focus remains on making implants and related procedures as comfortable and painless as possible among patients. 

Overview of segments and their growth prospects 

The report finds that as of 2012, metals as a biomaterial for implantable devices constituted the largest share within the global biomaterials market. The polymer biomaterials segment came a close second and continues to exhibit promising growth. TMR analysts predict that the polymers segment will witness the fastest growth within the biomaterials market for implantable devices between 2013 and 2019. 

According to the report, as of 2012, orthopedic applications were seen to hold a considerable share in the global biomaterials market for implantable devices because of a high number of knee and hip replacement procedures. In the near future, the biopolymers segment will receive impetus from the ophthalmic applications.

The report also finds that countries such as United States, Germany, Canada, France, Italy, U.K., and Spain are recording a high number of medical implant procedures, whereas the same remain sluggish in other regions. North America is the largest biomaterials market for implantable devices with Europe taking the second place globally. But the competition here remains cutthroat and this has prompted many players to venture into hitherto untapped markets in the Asia-Pacific region, such as Japan, China, South Korea, India, and Taiwan.

Request a Custom Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2384

Companies mentioned in the biomaterials market for implantable devices study

The report profiles prominent names in the global biomaterials market for implantable devices, such as: AdvanSource Biomaterials Corporation, Biomet, Inc., Celanese Corporation, Collagen Matrix, Inc., Ceradyne, Inc., DuPont, Evonik Industries AG, Royal DSM, Corbion Purac, and Invibio, Inc.

Small Molecule Targeted Cancer Therapy Market to Lead in 2016!

Small molecule targeted cancer therapies are drugs designed to block the growth of cancerous cells. Conventional cytotoxic medications and chemotherapies usually destroys rapidly dividing cancer cells by inhibiting cell division process. However, small molecule targeted therapies destroys cancerous cells with fewer side effects and high precision. Small molecule targeted cancer therapies can be used for the treatment of various cancers such as prostate cancer, multiple myeloma, breast cancer, lymphoma, melanoma and other cancers.

Targeted cancer drugs are broadly classified as follows:

• Small Molecules
• Monoclonal Antibodies
• Small Molecule Drug conjugates

Small molecules can further be classified as follows:

• Small molecule proteasome inhibitor (e.g. Bortezomib)
• Small molecule cyclin-dependent kinase inhibitor (e.g. Seliciclib)
• Small molecule tyrosine kinase inhibitor (e.g. Imatinib)

Geographically, North America is the leading market due to the rise incancer cases. According to the International Agency for Research on Cancer (IARC), around 13 million new cancer cases has been diagnosed worldwide. Moreover, according to the World Cancer Report, incidence rate of cancer could further rise by 50% to 15 million new cancer cases by 2020. Furthermore, the European and Asian-Pacific regions are expected to witness increased market traction due to commercialization of target oriented economic drugs.

Avail a Sample Copy: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2107

The major factors driving this market are rise in incidence rate of cancer, minimal adverse effects, targeted approach and high adoption rate. Additionally, more number of blockbuster drugs such as Novartis’s Glivec are losing their patents, leaving significant opportunities for manufacturers of targeted cancer drugs. However, high developmental costs, stringent regulatory policies andlow awareness are some of the restraints that could impede the growth of the market.

Some of the market players in this industry segment are Abbott Laboratories, Bayer HealthCare AG, Boehringer Ingelheim GmbH, CytokineticsInc., GlaxoSmithKline plc, Hospira Inc. , OncoGenex Pharmaceuticals Inc., and others.

Pharmerging Market: BRIC Nations to Drive Market Growth during 2015-2023!

A robust revenue growth of the global pharmaceutical market is poised to break horizon from the pharmerging market. Sales growth in the matured markets such as the U.S., Canada, Western Europe, U.K., and Japan is expected to slow down owing to patent expirations followed by the prevalence of low-cost generics. Introduction of new molecular entities will only drive these shrinking (matured) markets in future. However, as research consumes long periods and huge costs, pharmaceutical multinationals are eyeing the pharmerging market to offset for their investments and sustain a modest growth in the global pharmaceutical market. 

IMS has defined pharmerging markets or countries as those having a per capita GDP threshold of USD 25,000 and more than USD one billion spending growth from 2012 to 2016. Thus includes 21 countries which are identified based on the IMS defined parameters coupled with the macroeconomic factors and respective pharmaceutical market forecasts. IMS estimates that these 21 pharmerging markets will add USD 187 billion in annual sales to the global pharmaceutical market between 2012 and 2017. This value represents two third of the global pharmaceutical market growth which will be an increase of global share from 23% in 2012 to 33% in 2017. The BRIC nations i.e. Brazil, Russia, Indian and China will lead the pharmerging market. 

IMS has classified the pharmerging markets into three categories as tier 1, tier 2 and tier 3 markets.

Tier 1 pharmerging market includes China which is the largest and fastest growing pharmaceutical market. It will be the largest pharmerging market supported by the growing healthcare spending by Chinese government, implementation of the four year plan (2012 – 2015) for the prevention and control chronic diseases and drug cost lowering measures. Tier 2 category includes India, Brazil and Russia. Pharmaceutical market in these countries is expected to be driven by rising government healthcare expenditure, increasing purchasing power of general population, roaring access to medicines, rising and aging population and growing burden of chronic diseases. Tier 3 category includes the rest 17 countries which is further differentiated into two groups based on the average pharmaceutical spend per capita.

The spending growth in the pharmerging market is expected to grow with a CAGR of 12% to 15% which will expedite the market growth in these countries. Moreover, the pharmerging market is witnessing an increase in mergers and acquisitions among multinationals, to seize best of the opportunities in these revenue driver markets. For instance, Abbott Laboratories acquired Piramal Healthcare in 2010 becoming a leader in the Indian Pharmaceutical Market. Besides, Eli Lilly expanded a strategic partnership with Chinese manufacturer Novast Laboratories Ltd. in 2011 to provide Chinese patients with high-quality generic medicines. Such activities are expected to grow further which will boost the pharmerging markets further in the near future. Moreover, apart from the inorganic route, multinationals are also growing through organic route by investing in these countries to establish their research or manufacturing facilities. Greenfield investment will prove to be a long term boon for these pharmerging countries. One of the biggest challenges faced by the multinationals in the pharmerging market is pricing pressure which impacts the profit margin of these companies. Big pharmaceutical companies need to lower their prices to compete in the local market. 

Dietary Supplements Market Benefits from Changing Nutrition Intake in Emerging Economies

Transparency Market Research presents a market study on the global dietary supplements market, titled “DietarySupplements Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast 2014 – 2020”. The report serves as a useful guide for insights into the development of this market during the forecast period from 2014 to 2020.

The report presents projections of the newer trends that will define the dietary supplements market in the emerging economies of Asia Pacific and Latin America, which will have a significant influence on the growth trajectory of the global market. The analysis can help market players to tap into new opportunities that will open in these emerging regions in the foreseeable years.

The research report examines the global dietary supplements market from a comprehensive viewpoint. In this context, various dietary supplement products, age-specific supplement products, mode of consumption, market practices, trends, and regulatory mandates are some of the aspects that have been discussed in this report. Other than this, the leading and emerging product categories of dietary supplements are discussed at length in the report.

Dietary supplements are dietary products that are used to treat or prevent nutritional deficiencies. These products are typically used with the intent to supplement table food and not replace regular food, as stipulated by the U.S. Food and Drug Administration (FDA) for the utilization of these products. Dietary supplement products consist of vitamins, minerals, extracts, metabolites, herbs, amino acids, concentrates, and constituents.

Get a Copy of Sample Research on Dietary Supplements Market 

Age-specific product composition and oral ingestion are two features of dietary supplements that aid their popularity.

Over the past few years, the global dietary supplements market has witnessed phenomenal growth due to several reasons. This market has been substantially benefitted with the economic development in Asia Pacific. In this region, increasing purchasing power has been a significant reason for the adoption of Western lifestyle practices for nutritional requirements; intake of convenient ready-to-eat meals and dietary supplements to name a few.

Increasing awareness about nutrition and wellbeing, rising geriatric population, and high incidence of chronic and lifestyle diseases are some other factors favoring the development of the global dietary supplements market.

The report divides the global dietary supplements market on the basis of age, product type, and geography. Age-wise, infants, pregnant women, adults, and elderly persons are the segments of this market. Dietary supplements are formulated to meet the specific dietary and nutritional requirement of each age group.

The regional dynamics of the market are a vital indicator that determines the success of product development and marketing initiatives. Because dietary choices and nutritional deficiencies vary from country to country, substantial research needs to support product development to gain consumer confidence for the utilization of these products. Recommendations from personal relations encourage the utilization of these products across many cultures.

Corporate Wellness Market Spreading Wings Across Various Industries

Sedentary lifestyle of most of the corporate employees have added to the coverall pool of individuals suffering from hypertension, obesity, depression and other diseases such as diabetes, and cardiovascular diseases. Indirectly this has increased expenses for the corporations, as companies have to spend more on human resource management. To tackle the problem, corporate wellness initiatives are taken by companies to improve and maintain the health of employees. These programs help companies in many ways in reducing attrition rate and increasing productivity. Company profits are negatively affected by reduced productivity as a result of absenteeism. This can be prevented through a various measures to improve employee wellbeing. Regular fitness activities also motivate employees at work place and helps in reducing the overall healthcare costs. Workplace is also an important destination for increasing health awareness as employees spend most of their time at work. Consistent rise in the healthcare costs and discounts offered for employees participating in wellness programs, increased demand for corporate wellness services. Corporate wellness industry primarily involves fitness consultants, nutrition consultants, psychological therapists, and organizations who offer all the aforementioned services under a single roof. 

Government initiatives in mandating companies to implement well programs for employees will boost the market growth. In the U.S., with recent reforms in the Affordable Care Act increased the cap on incentives granted to employees for participating in health related wellness programs from 20% to 30% of the total cost. Such reforms will motivate employees to actively participate in the corporate wellness programs. Employee retention is also major issues corporate across the globe are facing today. Implementing corporate wellness programs will help in retaining valuable human resource as it increases employee satisfaction and motivates employees to perform better.

Get a Free Brochure of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4743

Earlier corporate wellness programs were implemented in larger organizations, which had the funds to implement such policies. But with increasing adoption of the programs in smaller organizations, the market is expected to propel at a faster rate in the future. Increasing industrialization in developing counties will also support the market growth. Employers are now committed to improving health of their employees. Corporates are conducting lifestyle coaching, biometric screenings; and are also encouraging service providers to synchronize hospital care as well. Companies are also looking forward to implement evidence based treatment schemes for employees. Corporate wellness programs are thus emerging as a routine employer sponsored initiative for health improvement of employees.

The corporate wellness programs find success in proper execution of the plan, where employee’s active participation is a key factor and companies must implement corporate wellness programs as a long term process for better results. Proper education and awareness for the wellness programs is necessary for its effective implementation. Currently major restraint for the corporate wellness market is the inefficient execution of plan which has ultimately resulted to increased costs for the companies. Employers need to discover efficient and effective models to implement the wellness programs. Although reward based approach has been successful in many organizations, better models beneficial to employers as well as employees will ensure deeper market penetration.

For more Trending Reports Visit our Blog: http://www.tmrblog.com/

Talks on the Future of Stem Cells - Trends and Innovations in Healthcare

As stem cells studies advance, stem cell therapy is looked upon as the go-to treatment option for a number of medical conditions. In a breakthrough development in stem cell studies, researchers at Massachusetts Institute of Technology (MIT) have developed a new programming technique that will allow the production of different types of tissues on-demand on a chip. Treatments for autoimmune diseases such as rheumatoid arthritis and growing tissues on-demand for organ replacement is not a faraway reality.

The global stem cells market is divided on the basis of product, application, technology, and

geography in this report. The research report provides historical and forecast analysis of market size, growth trends, and vital established and emerging growth areas in the global stem cells market. The report serves as a valuable guide for understanding the developments in the global stem cells market during the forecast period. Research data has been collated and presented in a crisp format. 

Using graphs and illustrations, the market study presents the current competitive landscape of the global stem cells market with changes in market hierarchy expected during the forecast period. The major companies that are involved in the business of stem cells are mentioned and are profiled for their key attributes.

Request a Sample copy of Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Overview of Global Stem Cells Market    

The global stem cells market was valued at US$26.23 bn in 2013. Consistent research studies around the world to discover the potential of stem cells for the treatment of several medical conditions will lead the market to rise at a 24.2% CAGR from 2012 to 2018. Owing to this, the global stem cells market will be valued at US$119.52 bn by the end of 2018.

Some of the factors that are driving the global stem cells market are: a growing number of stem cell banks, government support for clinical research and stem cell therapy advancements boosting medical tourism for recuperative purposes, and unmet medical needs. 

Stem cells are undifferentiated cells that have the remarkable potential to differentiate into several cell types during the early period of growth. These cells can differentiate, either to function as a stem cell or to develop into another cell type with a more specialized function, such as a red blood cell, brain cell, or muscle cell.

By product type, adult, induced pluripotent, very small embryonic-like, human embryonic, and rat neural stem cells are the segments of this market. Of these, adult stem cells account for the largest market share due to a relatively easier procedure to harvest these cells and higher chances of acceptance by the body. Umbilical cord, neuronal, hematopoietic, dental, and mesenchymal are the sub-segments of the adult stem cells segment. Culture, in-vitro fertilization, expansion and sub-culture, isolation, and cryopreservation are the segments that divide the market on the basis of technology. Application-wise, neurology, oncology, cardiovascular, wound care, diabetes, incontinence, orthopedics, hematology, myocardial infarction, spinal cord injuries, liver disorders, and others are the segments of the global stem cells market.

Regional Analysis: http://www.tmrblog.com/2015/12/stem-cells-market.html

North America is a significant market for stem cells accounting for more than 25% of the global market in 2011.

Major Companies in Global Stem Cells Market

STEMCELL Technologies Inc., Biotime Inc., Cellular Engineering Technologies, Celgene Corporation Inc., Brainstorm Cell Therapeutics, Bioheart, Osiris Therapeutics, Cytori Therapeutics Inc., Cellartis AB, California Stem Cells Inc., Angel Biotechnology, and Advanced Cell 

LATAM Cord Blood Banking Services Market Poised to Reach US$445.4 mn by 2023

Cord blood banking refers to collection and preservation of blood derived from the umbilical cord, thus saved for future therapeutic and research applications. Umbilical cord blood is observed to be a potential source of progenitor cells, which can be used for reconstitution of tissue, organs and other functional areas. Cord blood transplantation is being recommended for a variety of diseases which include conditions such as leukemia, sarcoma, lymphoma, immune conditions and even metabolic disorders. Over the last two decades, the global stem cell therapeutics industry has experienced impressive growth. Stem cells are the progenitors of all hematopoietic cells that generate red and white blood cells and blood platelets. These cells can be isolated and further transferred to a patients suffering from serious blood disorders and other chronic conditions. Moreover, cord blood stem cells are observed to be convenient to harvest and can be stored for decades, their rejection rate is less than that of bone marrow transplant and possess low infection risk. Large and easy availability of cord blood units also widens the scope of transplant options, especially for patients with mixed ethnicity. However, cord blood banking market in LATAM is in process of evolution and expected to grow at significant rate due to favorable changes expected to carry out by revising government policies and regulations.

Get a Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8413

The LATAM cord blood banking market is be categorized on the type of storage option into public and private cord blood banking. High incidence of genetic disorders and better apprehension of such diseases due to availability of high end diagnostic services has been highly instrumental in rendering market dominance to private cord blood banking services. However, relatively high service charges for cord blood banking and the general opinion among physicians about less possibility of the use of such stored units may restrict the growth of private cord banking services market in a few countries of LATAM such as Brazil, Mexico, Argentina, Peru and others.

Advancement in stem cell therapy research has encouraged the practice of cord blood banking in Latin America due to rapidly increasing technological and infrastructural development in the region. Major countries such as Brazil, Mexico, and Colombia are focusing on expansion of cord blood bank networks. Most of the cord blood banks are supported by government funding. However, several private cord blood banks have already entered the market and many others are planning to enter the market in Latin America in the near future. Some of the established cord blood banks in Latin America also operate in the field of tissue engineering, non-invasive prenatal tests and stem cell development. Numerous countries in Latin America are on the verge of taking initiatives to decrease the drawbacks of public and private banking by implementing a hybrid model. The hybrid cord blood banking model is expected to involve storage of the sample in two portions. One portion is for the usage of the child or solely its close family member, while the other portion is stored as public donation.

Visit to Get Regional Analysis: http://www.europlat.org/latam-cord-blood-banking-services-market-to-reach-us445-4-mn-by-2023-brazil-leads-in-revenue-generation.htm

The cord blood banking services industry is highly fragmented in nature and is characterized by diverse policies which vary from one country to other in LATAM. At present there is a division between private and public cord blood banking companies in which, private cord blood banks serve only individual families, whereas public banks serve the general population. Private cord blood banks offer cord blood storage (autologous donation) for personal use of donors and their family in consideration of an annual payment. Private cord blood banks promote the concept that though the probability of requiring autologous cord blood is currently less for hematopoietic conditions, its usage in treating non-hematopoietic conditions is more prevalent and is estimated to increase in the future. Majority of private cord blood banks use similar storage technologies as those of public banks. However, the method of collection varies in the sense that private banks send collection kits to patients who in turn hand them over to the obstetrician.